BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31345706)

  • 21. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
    Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
    Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disorganization and cognitive impairment in schizophrenia: New insights from electrophysiological findings.
    Vignapiano A; Koenig T; Mucci A; Giordano GM; Amodio A; Altamura M; Bellomo A; Brugnoli R; Corrivetti G; Di Lorenzo G; Girardi P; Monteleone P; Niolu C; Galderisi S; Maj M;
    Int J Psychophysiol; 2019 Nov; 145():99-108. PubMed ID: 30898578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: the effects of test battery in a randomised controlled trial.
    Lees J; Michalopoulou PG; Lewis SW; Preston S; Bamford C; Collier T; Kalpakidou A; Wykes T; Emsley R; Pandina G; Kapur S; Drake RJ
    Psychol Med; 2017 Oct; 47(13):2358-2368. PubMed ID: 28464963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships between abnormal neural activities and cognitive impairments in patients with drug-naive first-episode schizophrenia.
    Yan W; Zhang R; Zhou M; Lu S; Li W; Xie S; Zhang N
    BMC Psychiatry; 2020 Jun; 20(1):283. PubMed ID: 32503481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive dysfunction correlates with elevated serum S100B concentration in drug-free acutely relapsed patients with schizophrenia.
    Chen S; Tian L; Chen N; Xiu M; Wang Z; Yang G; Wang C; Yang F; Tan Y
    Psychiatry Res; 2017 Jan; 247():6-11. PubMed ID: 27863321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients.
    Zhang B; Han M; Tan S; De Yang F; Tan Y; Jiang S; Zhang X; Huang XF
    Sci Rep; 2017 Sep; 7(1):11821. PubMed ID: 28928440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the optimal neuropsychological test battery for schizophrenia in China?
    Shi C; Kang L; Yao S; Ma Y; Li T; Liang Y; Cheng Z; Xu Y; Shi J; Xu X; Zhang C; Franklin DR; Heaton RK; Jin H; Yu X
    Schizophr Res; 2019 Jun; 208():317-323. PubMed ID: 30718121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study.
    Olivier MR; Killian S; Chiliza B; Asmal L; Schoeman R; Oosthuizen PP; Kidd M; Emsley R
    Psychol Med; 2015 Oct; 45(13):2873-83. PubMed ID: 25998030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study.
    Kern RS; Gold JM; Dickinson D; Green MF; Nuechterlein KH; Baade LE; Keefe RS; Mesholam-Gately RI; Seidman LJ; Lee C; Sugar CA; Marder SR
    Schizophr Res; 2011 Mar; 126(1-3):124-31. PubMed ID: 21159492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients.
    Georgiades A; Davis VG; Atkins AS; Khan A; Walker TW; Loebel A; Haig G; Hilt DC; Dunayevich E; Umbricht D; Sand M; Keefe RSE
    Schizophr Res; 2017 Dec; 190():172-179. PubMed ID: 28433500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).
    McCleery A; Green MF; Hellemann GS; Baade LE; Gold JM; Keefe RS; Kern RS; Mesholam-Gately RI; Seidman LJ; Subotnik KL; Ventura J; Nuechterlein KH
    Psychol Med; 2015; 45(12):2657-66. PubMed ID: 25916421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MATRICS cognitive consensus battery (MCCB) performance in children, adolescents, and young adults.
    Nitzburg GC; Derosse P; Burdick KE; Peters BD; Gopin CB; Malhotra AK
    Schizophr Res; 2014 Jan; 152(1):223-8. PubMed ID: 24321710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of cigarette smoking with cognitive impairment in male patients with chronic schizophrenia.
    Wei S; Wang D; Wei G; Wang J; Zhou H; Xu H; Xia L; Tian Y; Dai Q; Zhu R; Wang W; Chen D; Xiu M; Wang L; Zhang XY
    Psychopharmacology (Berl); 2020 Nov; 237(11):3409-3416. PubMed ID: 32757027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What does the Managing Emotions branch of the MSCEIT add to the MATRICS consensus cognitive battery?
    DeTore NR; Mueser KT; McGurk SR
    Schizophr Res; 2018 Jul; 197():414-420. PubMed ID: 29486955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of the Chinese version of the MATRICS Consensus Cognitive Battery to assess cognitive functioning in individuals with high risk for psychosis, first-episode schizophrenia and chronic schizophrenia: a systematic review and meta-analysis.
    Cai B; Zhu Y; Liu D; Li Y; Bueber M; Yang X; Luo G; Su Y; Grivel MM; Yang LH; Qian M; Stone WS; Phillips MR
    Lancet Reg Health West Pac; 2024 Apr; 45():101016. PubMed ID: 38699289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].
    Rodríguez-Jiménez R; Bagney A; Moreno-Ortega M; García-Navarro C; Aparicio AI; López-Antón R; de la Oliva J; Jiménez-Arriero MÁ; Santos JL; Lobo A; Palomo T
    Rev Neurol; 2012 Nov; 55(9):549-55. PubMed ID: 23111994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are negative symptoms really related to cognition in schizophrenia?
    Bagney A; Dompablo M; Santabárbara J; Moreno-Ortega M; Lobo A; Jimenez-Arriero MA; Palomo T; Rodriguez-Jimenez R
    Psychiatry Res; 2015 Dec; 230(2):377-82. PubMed ID: 26454405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia.
    Kumar S; Mulsant BH; Tsoutsoulas C; Ghazala Z; Voineskos AN; Bowie CR; Rajji TK
    Int J Geriatr Psychiatry; 2016 Oct; 31(10):1116-23. PubMed ID: 27428251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardio-respiratory fitness is associated with a verbal factor across cognitive domains in schizophrenia.
    Holmen TL; Engh JA; Andersen E; Andreassen OA; Martinsen EW; Bigseth TT; Bang-Kittilsen G; Egeland J
    Schizophr Res; 2019 Apr; 206():157-162. PubMed ID: 30528313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.